Depression in young people may soon be treated with greater precision, as researchers in Western Australia investigate whether genetic information can help clinicians choose antidepressants more effectively. The pharmacogGENEtics in Youth Depression, or GENE-YD, study examines the feasibility of using pharmacogenetic testing to personalize antidepressant pharmacotherapy for young Australians. Published in Translational Psychiatry, the study brings together psychiatry, genetics and clinical implementation in an effort to address one of the most frustrating problems in depression care: the unpredictable way individuals respond to the same medication.
Antidepressants are widely prescribed, but their effects vary dramatically from one person to another. A medicine that improves mood and restores functioning for one patient may produce little benefit, troubling side effects or both in another. Clinicians typically select treatments through a process of trial and error, adjusting the dose or changing medications when the initial approach fails. This process can take weeks or months, a particularly important concern for adolescents and young adults, whose depression may interfere with education, relationships, work and long-term development.
Pharmacogenetics seeks to reduce some of that uncertainty by examining how inherited genetic differences influence the way the body handles medicines. Variants in genes involved in drug metabolism can affect how quickly an antidepressant is broken down, how much of the active compound reaches the bloodstream and whether side effects are more likely. Other genetic factors may influence drug transport, receptor activity or broader biological pathways linked to treatment response. The goal is not to identify a single “depression gene,” but to use multiple pieces of biological information to support more informed prescribing.
The GENE-YD study focuses specifically on young people in Western Australia, a population whose needs have often been underrepresented in pharmacogenetic research. The investigators, led by B. Roberts, Z. Cooper and A. Miljevic, describe the project as a feasibility study, meaning that an important objective is to determine whether this type of personalized treatment program can work in real-world clinical settings. Feasibility research can examine whether participants are willing to provide genetic samples, whether testing can be completed efficiently, whether results can be returned in a clinically useful format and whether healthcare professionals can incorporate those results into treatment decisions.
That practical foundation is crucial because genetic testing alone does not automatically produce better care. A laboratory report may identify that a patient metabolizes a particular medicine more slowly or rapidly than average, but clinicians must still consider symptom severity, previous treatment history, coexisting medical conditions, other medications, family preferences and the patient’s own goals. Depression is biologically and psychologically complex, and pharmacogenetic information is most useful when treated as one component of a broader clinical assessment rather than as a definitive prescription.
The study’s focus on young people also raises important questions about communication and consent. Genetic information can be sensitive, particularly when participants are minors or are receiving care with the involvement of parents and guardians. Researchers must explain what the test can and cannot reveal, how results will be stored, who will have access to them and whether the information could have implications for relatives. A successful personalized-medicine program therefore depends not only on laboratory accuracy, but also on trust, privacy protections and clear conversations between clinicians, young patients and families.
The potential appeal of pharmacogenetic guidance is easy to understand. If testing can indicate that a patient is likely to experience unusually high drug exposure at a standard dose, a clinician might consider a lower starting dose or a different medicine. If a patient is predicted to process a medication rapidly, the result could prompt closer monitoring or a discussion of alternative treatments. These decisions would still require clinical judgment, but they could help reduce avoidable side effects and shorten the period of unsuccessful experimentation that often accompanies antidepressant treatment.
At the same time, the field has faced questions about how large and reliable the benefits are across different populations and healthcare systems. Genetic variants do not explain every reason a treatment succeeds or fails, and the usefulness of a test can depend on the specific medicines included, the quality of the evidence behind the genetic recommendations and the way results are integrated into care. A feasibility study such as GENE-YD is therefore an essential step before larger trials can determine whether pharmacogenetic-guided prescribing improves remission rates, speeds recovery, reduces adverse effects or proves cost-effective.
The Western Australian setting may also provide valuable insight into how precision psychiatry can be implemented beyond major research centers. If young people and clinicians can engage successfully with the process, the findings could help shape future studies involving larger and more diverse groups. Ultimately, the promise of GENE-YD is not that a genetic test will replace psychiatric expertise, but that it may give clinicians another tool for making treatment more individual, informed and responsive. For families confronting the uncertainty of youth depression, even a modest reduction in trial and error could represent a meaningful advance.
Subject of Research: Pharmacogenetic personalization of antidepressant treatment for young people in Western Australia
Article Title: The pharmacogGENEtics in Youth Depression (GENE-YD) study for personalizing antidepressant pharmacotherapy for young Western Australians – A feasibility study
Article References: Roberts, B., Cooper, Z., Miljevic, A. et al. “The pharmacogGENEtics in Youth Depression (GENE-YD) study for personalizing antidepressant pharmacotherapy for young Western Australians – A feasibility study.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04321-x
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41398-026-04321-x
Keywords: youth depression, pharmacogenetics, antidepressants, personalized medicine, psychiatric treatment, Western Australia, feasibility study, precision psychiatry
